Company Resources

New Market Intelligence Report Reveals $15B Opportunity in Chronic Cough Therapeutics, With Zero FDA-Approved Competitors

Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.

Scoping Review in Lancet Digital Health Highlights the Importance of Objective Cough Counting Data in Disease Management

Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data

New Clinical Trial Evidence Validates Effectiveness of Hyfe’s Digital Chronic Cough Platform

Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.

Hyfe to Launch World’s First Prescription Digital Therapeutic to Treat Chronic Cough

Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.

Refractory Chronic Cough (RCC) Therapy May Be One of the Most Asymmetric Bets in Respiratory

CHEST 2025: Improving Access to Chronic Cough Treatment Through a Digital Therapeutic Solution (Pharmacy Times)

Q&A: The New Standard for Measuring Cough with Tamsin Chislett

Digital Therapeutics Global Market Map (2025)